DEFENSIN THERAPEUTICS ApS: Financial statements 2022
CVR: 35513280
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
DEFENSIN THERAPEUTICS ApS (CVR 35513280) has filed annual accounts for 2022. In 2022, the company reported a net result of DKK -473,890 compared with DKK -365,611 the year before. Equity in the 2022 report amounted to DKK 1,667,999. The solvency ratio was 94.5%.
- Profit/Loss
- DKK -473,890
- Equity
- DKK 1,667,999
- Total Assets
- DKK 1,765,038
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | - | -474K | 1.7M | - |
| 2021 | 0 | - | -366K | 2.1M | - |
| 2020 | - | - | -2.3M | 2.5M | 0 |
| 2019 | - | - | -1.7M | 4.8M | 1 |
| 2018 | - | - | -3M | 1M | - |
Official annual report
Keep an eye on DEFENSIN THERAPEUTICS ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
DEFENSIN THERAPEUTICS ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -365,611.
About DEFENSIN THERAPEUTICS ApS
DEFENSIN THERAPEUTICS ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Peter Hviid Nordkild. The board consists of Ejner Bech Jensen (chair), Matthew Alister Cooper, Peter Hviid Nordkild and Robert Ehehalt. The company's owners include NOVOZYMES A/S, PN INVESTMENT ApS and NEVE INVEST ApS. The company has 0 employees (2018). In 2025, the company reported a gross profit of DKK -538,913 and a net result of DKK -539,063 compared with DKK -130,534 the year before. Equity in the 2025 report amounted to DKK 774,437.